Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

In the seven-plus years since Bayer closed its mammoth buyout of Monsanto, the combined company has struggled to contain ...

McKinney explains how tariff concerns drove last year’s manufacturing surge and why Atradius expects a period of stabilization ahead. He also discusses how companies are weighing the risk of future ...

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply ...